Mitchell Parma, MD, discusses an analysis of survival benefit with immunotherapy in patients with NSCLC brain metastases.
Mitchell Parma, MD
Advertisement
Mitchell Parma, MD, a clinical fellow in Hematology/Oncology at the University of Texas MD Anderson Cancer Center
Articles by Mitchell Parma, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Gedatolisib Plus Fulvestrant ± Palbociclib for Hormone Receptor–Positive, HER2-Negative, Locally Advanced/Metastatic Breast Cancer
2
FDA Awards Traditional Approval to Selpercatinib for RET+ Advanced Solid Tumors
3
Research Rewind: Phase 3 Breast Cancer Data Highlights From Q2 2026
4
FDA Grants Fast Track Designation to SOT109 in Advanced Colorectal Cancer
5